格隆汇1月23日丨联化科技(002250.SZ)公布，预计2025年归属于上市公司股东的净利润35,000.00万元– 42,000.00万元，比上年同期增长239.35%–307.22%，扣除非经常性损益后的净利润33,000.00万元– 41,000.00万元，比上年同期增长171.87%–237.78%。 1、2025 年度公司整体产能利用率提升，从而增强了公司的盈利能力。2、2025 年度国际汇率波动较 大，公司存在境外子公司，产生了汇兑收益。四、风险提示1、本次业绩预告系公司财务部门初步估算 的结果，公司2025年年度具体财务数据以公司公布的2025年年度报告为准。2、公司将严格依照有关法 律法规的规定和要求，及时做好信息披露工作，敬请广大投资者注意投资风险。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

Core Viewpoint - Lianhua Technology (002250) expects a significant increase in net profit for 2025, projecting a growth of 239.35% to 307.22% year-on-year, with estimated net profit ranging from 350 million to 420 million yuan [1] Group 1: Financial Performance - The company anticipates a net profit of 350 million to 420 million yuan for 2025, indicating a substantial year-on-year growth [1] - The expected growth is attributed to an increase in overall capacity utilization, which enhances the company's profitability [1] Group 2: External Factors - The company has foreign subsidiaries, which have resulted in exchange gains due to significant fluctuations in international exchange rates [1]

证券代码：002250 证券简称：联化科技 公告编号：2026-001 联化科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本业绩预告未经过注册会计师预审计。公司已就本次业绩预告有关事项与会 计师事务所进行预沟通，公司与会计师事务所在本次业绩预告方面不存在重大分 歧。 三、业绩变动原因说明 1、2025 年度公司整体产能利用率提升，从而增强了公司的盈利能力。 2、2025 年度国际汇率波动较大，公司存在境外子公司，产生了汇兑收益。 四、风险提示 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：ð 扭亏为盈 √同向上升 ð 同向下降 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 盈利：35,000.00 | 万元–42,000.00 万元 | 盈利：10,313.90 | 万元 | | | | 比上年同期增长：239.35%–307.22% ...

开源证券认为，针对农药原药及中间体(原料)出口退税率取消和下调，短期来看，出口成本上升+国内 春耕旺季来临+"抢出口"预期，助力农药景气反转、量价齐升。2022Q4以来，供需错配导致多数农药产 品价格震荡下行，国内旺季来临而出口成本抬升，叠加海外存在提前备货、集中采购的动力，或助力草 铵膦等含磷农药及中间体量价齐升、盈利修复。 近日，财政部、税务总局联合发布《关于调整光伏等产品出口退税政策的公告》，明确自2026年4月1日 起，取消光伏等产品增值税出口退税，其中多项与农药及含磷化工品相关，包括：(1)农药原药和中间 体(原料)：草铵膦、精草铵膦(L-草铵膦)、敌百虫、敌敌畏、乙酰甲胺磷、氟苯虫酰胺、三乙膦酸铝、 马拉硫磷、双环磺草酮、烯禾啶、乙烯利、其他非卤化有机磷衍生物(包括草甘膦，草甘膦出口退税已 取消，此次不受影响)等，既包括草铵膦、精草铵膦、烯禾啶等产能过剩品种，也包括了一些高毒禁限 用品种。此外，本次涉及的商品代码为29章，农药制剂属于38章，暂没有调整。 (2)无机磷酸盐：六氟磷酸锂、食品级的正磷酸氢钙(磷酸二钙)、食品级的三磷酸钠(三聚磷酸钠)、其他 三磷酸钠(三聚磷酸钠)、食品级的六偏磷酸钠。 ...

Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report emphasizes the continuous catalysts in the small nucleic acid industry for 2026, highlighting the potential investment opportunities within the industry chain [5][19] - The report suggests a positive outlook for innovative drugs and the industry chain, with expectations of increased global participation from domestic innovative drug companies and the introduction of more innovative projects in 2026 [11][30] - The report identifies the medical device sector as a potential area for capital inflow, with signs of improvement in leading companies and a reduction in the pressure from centralized procurement [13][34] Summary by Sections Industry Overview - The closing index for the industry is at 8657.19, with a 52-week high of 9323.49 and a low of 6876.88 [2] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 0.68% from January 12 to January 16, 2026, underperforming the CSI 300 index by 0.11 percentage points [9][28] - The medical research outsourcing sector performed the best among sub-sectors, rising by 3.69%, while the vaccine sector declined by 3.43% [10][28] Innovative Drugs and Industry Chain - The JPM conference highlighted the strengthening of industry development logic, with increased merger and acquisition activity among multinational corporations and breakthroughs in domestic innovative drugs [11][30] - The report recommends focusing on companies with high certainty and relatively low disruption expectations, such as Innovent Biologics and others [11][30] Medical Devices - The report notes that the medical device sector is showing signs of improvement, with leading companies reporting better performance in Q3 [13][34] - The report suggests that the pressure from centralized procurement is decreasing, which may lead to valuation recovery [13][34] Small Nucleic Acid Drugs - The report highlights several key clinical trials and data readouts expected in 2026 from companies like Alnylam, Arrowhead, and Wave Life Sciences, indicating a significant focus on the weight loss and CNS fields [6][8][27] - The report encourages attention to domestic small nucleic acid-related companies and upstream industry chains [27] Investment Recommendations - The report suggests focusing on companies in the CXO and life science services sectors, as demand for overseas R&D and production outsourcing is expected to recover steadily [12][31] - It also highlights the potential for valuation re-evaluation opportunities in the biopharmaceutical sector, particularly for blood products and vaccines [32][33]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Core Viewpoint - The article emphasizes the ongoing integration of artificial intelligence (AI) in various industries, particularly in manufacturing and pharmaceuticals, driven by government policies and technological advancements [4][5][6]. Group 1: AI Integration in Manufacturing - The Chinese government has issued policies to promote the integration of AI in manufacturing, focusing on quality improvement and efficiency through technologies like large models and digital twins [4]. - Key players in the chemical industry, such as China National Petroleum, China Petroleum & Chemical, and China National Offshore Oil Corporation, are developing industry-specific AI models to enhance core business operations [5]. - Companies like Wanhua Chemical are leveraging third-party AI platforms to achieve cost reduction and efficiency in production management and material research [5]. Group 2: Growth of Small Nucleic Acid Drugs - The global market for small nucleic acid drugs has seen significant growth, with a compound annual growth rate (CAGR) of 217.8%, increasing from $0.1 billion in 2016 to $3.25 billion in 2021 [6]. - Projections indicate that the market for oligonucleotide drugs will exceed $15 billion by 2026, with a CAGR of 35% from 2020 to 2025 [6]. - The industry is expected to transition from technological breakthroughs to large-scale commercialization, indicating a promising future for the small nucleic acid drug sector [6]. Group 3: Key Players in Small Nucleic Acid Development - Bluestar Technology has established a comprehensive technology platform for small nucleic acids and peptide drugs, being one of only two global suppliers capable of providing integrated solutions for complex oligonucleotide synthesis [7]. - Lonza Technology is expanding its CDMO services globally, achieving significant progress in partnerships with leading pharmaceutical companies and enhancing its domestic collaborations [7].

Investment Rating - The industry investment rating is "Positive" (maintained) [2] Core Viewpoints - The report highlights the impact of the recent cancellation and reduction of export tax rebates on pesticides, particularly focusing on the potential for price increases and improved profitability for leading companies in the pesticide sector [5] - The report anticipates a reversal in the pesticide industry's performance due to rising export costs and the upcoming spring farming season, which is expected to boost demand and prices [5] - The ongoing "anti-involution" trend in the pesticide industry is expected to optimize supply and reshape value, encouraging companies to shift from low-end manufacturing to a focus on technology, branding, and service [5] Summary by Relevant Sections Industry Overview - The pesticide industry is experiencing a significant shift due to policy changes, with the cancellation of export tax rebates for various pesticide raw materials and intermediates, including glyphosate and other high-toxicity products [4][5] - China is projected to export 2.05 million tons of pesticides in 2024, with exports accounting for 90% of production [5] Market Dynamics - The domestic pesticide production peak season occurs from February to May, with a significant increase in demand for pesticide formulations during this period [5] - The report notes that the price of 95% glyphosate raw powder has recently increased to 46,000 yuan per ton, indicating a recovery in pricing [11] Key Companies and Recommendations - Recommended stocks include leading pesticide companies such as Yangnong Chemical, Limin Co., and Xingfa Group, which are expected to benefit from the price increases and the integrated "raw material-formulation" model [5] - Beneficiary stocks also include Jiangshan Chemical, Lier Chemical, and others involved in various segments of the pesticide supply chain [5]

Investment Rating - The report maintains an "Overweight" rating for the basic chemical industry [6] Core Insights - The integration of "AI+" in the chemical industry is being driven by national policies aimed at enhancing quality and efficiency through advanced technologies like large models and digital twins [1][2] - The global small nucleic acid drug market is experiencing rapid growth, with projections indicating a market size exceeding $15 billion by 2026, driven by technological breakthroughs and commercialization [3][33] - Key players like Bluestar Technology and Lianhua Technology are leading breakthroughs in small nucleic acid production and CDMO services, respectively [4][36] Summary by Sections AI Integration in Chemical Manufacturing - The chemical industry is advancing towards large-scale application of "AI+" through three main pathways: self-developed large models by leading companies, collaboration with third-party platforms, and investment in AI startups [2][27] - Major companies such as China National Petroleum, Sinopec, and China National Offshore Oil Corporation are embedding AI into core business processes to enhance operational efficiency [2][27] Small Nucleic Acid Drug Market - The small nucleic acid drug market has grown from $0.1 million in 2016 to $3.25 billion in 2021, with a compound annual growth rate (CAGR) of 217.8% [3][33] - The market is expected to continue its growth trajectory, with a forecasted CAGR of 35% from 2020 to 2025 [3][33] Key Players and Innovations - Bluestar Technology has established a comprehensive technology platform for the synthesis and purification of small nucleic acids, making it one of only two global suppliers with such capabilities [4][34] - Lianhua Technology is expanding its CDMO services for small nucleic acids, achieving significant progress in international market collaborations [4][36] Investment Recommendations - The report suggests focusing on leading companies in the chemical sector that leverage data for efficiency gains, such as China National Petroleum, Sinopec, and Wanhu Chemical [5][32] - In the small nucleic acid sector, attention is drawn to Bluestar Technology and Lianhua Technology for their strategic positions in the market [5][37]

Core Viewpoint - The agricultural pesticide sector is experiencing a significant upward trend driven by multiple favorable factors, including policy incentives, the upcoming spring farming season, and a recovery in global market demand [1][2]. Group 1: Policy Changes - The "One Certificate, One Product" policy will be fully implemented on January 1, 2026, aiming to eliminate the long-standing issues of "one pesticide with multiple names" and "certificate borrowing" in the industry [1]. - This policy is expected to compel companies to shift focus from "labeling" to "research and development," fostering competition based on technology, quality, and service, thereby promoting high-quality industry development [1]. Group 2: Export Tax Adjustments - The cancellation of export tax rebates for certain pesticide raw materials starting April 1, 2026, is anticipated to pressure profit margins for related companies in the short term [2]. - However, this adjustment may accelerate the elimination of outdated production capacity and encourage companies to transition to high-end products, enhancing product value [2]. - In 2024, China's pesticide formulation export value reached 61.36 billion, surpassing raw material exports for the first time, with a share of 54.12% [2]. Group 3: Demand Dynamics - The upcoming spring farming season is expected to release strong demand for pesticides, with an estimated 3.8 billion acres of crops affected by pests, leading to direct economic losses exceeding 42 billion [3]. - The industry has maintained an operating rate of over 80% for the past eight months, with inventory levels at their lowest since the beginning of 2024, indicating a favorable supply-demand balance [3]. Group 4: Benefiting Industries - The pesticide intermediate sector is likely to benefit from the rising demand for pesticide raw materials, with companies like Lianhua Technology expected to see performance growth due to stable demand from downstream clients [4]. - The phosphorus chemical industry will also benefit, as the recovery in pesticide demand will increase the consumption of upstream raw materials like phosphate rock and phosphoric acid [4]. - The integration of precision agriculture and the pesticide industry is expected to drive growth in the plant protection service and smart pesticide machinery sectors, with significant increases in the adoption of precision application equipment projected [5].